Summary of response, follow-up treatment, and relapse
| Outcome, n (%) . | MRD responders . | MRD nonresponders . | ||
|---|---|---|---|---|
| OS ≥30 mo (n = 10) . | OS <30 mo (n = 15) . | Total (N = 25) . | OS <30 mo* (N = 11) . | |
| Best response† | ||||
| CR | 7 (70) | 8 (53) | 15 (60) | 2 (18) |
| CRh | 2 (20) | 5 (33) | 7 (28) | 1 (9) |
| Hypocellular bone marrow | 1 (10) | 1 (7) | 2 (8) | 2 (18) |
| Partial remission | 0 (0) | 1 (7) | 1 (4) | 1 (9) |
| Allo-SCT after CR/CRh‡ | 5 (50) | 8 (53) | 13 (52) | 0 (0) |
| Allo-SCT after hypocellular bone marrow | 1 (10) | 1 (7) | 2 (8) | 1 (9) |
| Retreatment with blinatumomab | 1 (10) | 2 (13) | 3 (12) | 2 (18) |
| Relapse-free after blinatumomab | 6 (60) | 0 (0) | 6 (24) | 0 (0) |
| Blinatumomab treatment only | 2 (20) | 0 (0) | 2 (8) | 0 (0) |
| Blinatumomab and allo-SCT | 4 (40) | 0 (0) | 4 (16) | 0 (0) |
| Outcome, n (%) . | MRD responders . | MRD nonresponders . | ||
|---|---|---|---|---|
| OS ≥30 mo (n = 10) . | OS <30 mo (n = 15) . | Total (N = 25) . | OS <30 mo* (N = 11) . | |
| Best response† | ||||
| CR | 7 (70) | 8 (53) | 15 (60) | 2 (18) |
| CRh | 2 (20) | 5 (33) | 7 (28) | 1 (9) |
| Hypocellular bone marrow | 1 (10) | 1 (7) | 2 (8) | 2 (18) |
| Partial remission | 0 (0) | 1 (7) | 1 (4) | 1 (9) |
| Allo-SCT after CR/CRh‡ | 5 (50) | 8 (53) | 13 (52) | 0 (0) |
| Allo-SCT after hypocellular bone marrow | 1 (10) | 1 (7) | 2 (8) | 1 (9) |
| Retreatment with blinatumomab | 1 (10) | 2 (13) | 3 (12) | 2 (18) |
| Relapse-free after blinatumomab | 6 (60) | 0 (0) | 6 (24) | 0 (0) |
| Blinatumomab treatment only | 2 (20) | 0 (0) | 2 (8) | 0 (0) |
| Blinatumomab and allo-SCT | 4 (40) | 0 (0) | 4 (16) | 0 (0) |